1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

With Access Restricted, Aduhelm Appears Poised For A Slow Start

Payers Speak Out At ICER Public Meeting

 
• By Jessica Merrill

Reimbursement, health policy and medical experts predicted a slow rollout ahead for Biogen's new Alzheimer's treatment at a public meeting sponsored by ICER.

Slow launch
Market access is becoming a big issue for Aduhelm • Source: Alamy

Access to Biogen, Inc.'s new novel Alzheimer's disease therapy Aduhelm (aducanumab) will be limited while medical treatment centers establish treatment policies and while the Centers for Medicare and Medicaid Services (CMS) completes a National Coverage Determination analysis for amyloid-directed monoclonal antibody drugs, experts predicted during a public policy roundtable sponsored by the Institute for Clinical and Economic Review (ICER) on 15 July.

Just over one month after the US Food and Drug Administration granted a controversial accelerated approval for Aduhelm for the treatment of Alzheimer's disease, it increasingly appears that roadblocks are...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Lilly To Diversify Pain Pipeline With SiteOne Acquisition

 
• By Joseph Haas

Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

More from Therapy Areas

Lilly To Diversify Pain Pipeline With SiteOne Acquisition

 
• By Joseph Haas

Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

GlycoEra’s Series B Cash Will Fund Efforts To Take On FcRn Inhibitor Class

 
• By Joseph Haas

GlycoEra unveiled a $130m series B financing, saying the proceeds would enable it to take its first clinical candidate through proof-of-concept in autoimmune diseases.